Inc., a wholly owned subsidiary of Krystal Biotech, and initial safety data from the ongoing Phase 1 trial of Jeune’s lead product candidate, KB301 for treatment of aesthetic skin conditions.

G&G Biotechnology BV., announced today at the ... only lightweight breast implants and are set to transform breast aesthetics forever for both physicians and patients. (Logo: http ...

PITTSBURGH--(BUSINESS WIRE)--Krystal Biotech, Inc. (Nasdaq ... If ultimately successful, KB301 and any additional aesthetic programs will be developed through our wholly-owned subsidiary Jeune ...

Now in development, Elastagen’s tropoelastin tissue repair platform will include breakthrough treatments for acne scars, stretch marks, aesthetic ... Summit at Biotech Showcase, sharing exciting ...

PITTSBURGH, Aug. 25, 2020 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (Nasdaq ... If ultimately successful, KB301 and any additional aesthetic programs could represent an interesting strategic ...

EXTON, Pa.--(BUSINESS WIRE)-- Fibrocell Science, Inc. (OTCBB: FCSC), a biotechnology company focused on the development of autologous (personalized) cell therapies for aesthetic, medical and ...

Mr. Jin Xuekun, the CEO of Bloomage BioTech, said, "The investment shows GIC's recognition on our track record and future potential as well as our strategy of building up aesthetic medical ...